Leaders from across the industry met at Informa's Pharmaceutical Strategy conference and addressed some of the most critical issues facing the industry: pharma's tarnished reputation and drug pricing.
Across a panel of drug company and payer executives at PSA, one thing almost everyone agreed on is that the cost of drugs as a growing burden to patients is an issue that isn't going away – and industry needs better ways to measure value and adapt pricing accordingly.
High drug prices and their contribution to industry's negative image with the public were hot topics at Informa's Pharmaceutical Strategy...
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
EFPIA says reforms make the continent less attractive for innovative firms.
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
